Qingli Cui

机构：Zhengzhou University, Henan Cancer Hospital

发表论文 11 篇 · 总被引 149 次 · h-index 8

代表论文

• In situ decorated Au NPs on chitosan-encapsulated Fe3O4-NH2 NPs as magnetic nanocomposite: Investigation of its anti-colon carcinoma, anti-gastric cancer and anti-pancreatic cancer (2020 · International Journal of Biological Macromolecules · 被引 30)
• A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer (2021 · Drug Design Development and Therapy · 被引 29)
• Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance (2022 · Frontiers in Pharmacology · 被引 18)
• Aqueous extract of Taxus Chinensis (Pilger) Rehd inhibits lung carcinoma A549 cells through the epidermal growth factor receptor/mitogen-activated protein kinase pathway in vitro and in vivo (2014 · 中医杂志：英文版 · 被引 16)
• Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer (2022 · Frontiers in Oncology · 被引 12)
• Nanodrugs systems for therapy and diagnosis of esophageal cancer (2023 · Frontiers in Bioengineering and Biotechnology · 被引 11)